Rather than producing medicines through batch-wise, step-by-step processes, CONTINUUS Pharmaceuticals offers a breakthrough Integrated Continuous Manufacturing (ICM) technology for small molecule pharmaceuticals. The synthesis of the active ingredient and the final dosage form are integrated into a seamless process. This novel method will allow “on-demand” manufacturing of pharmaceuticals with significant advantages in production lead time, quality, and costs.
CONTINUUS Pharmaceuticals is a spin-out company from a multi-year collaboration between MIT and Novartis on Continuous Manufacturing. We specialize in end-to-end Integrated Continuous Manufacturing (ICM), with the application of novel process technologies that enable rapid production of pharmaceuticals at significantly reduced costs and better quality. With ICM, we will improve affordability and accessibility of pharmaceuticals on a global scale.
July 14, 2021
CONTINUUS Pharmaceuticals Opens New Laboratory and Introduces New Technology for High-potency Drug Development
June 12, 2021
ICM Factory Advisory Team
January 21, 2021
CONTINUUS Pharmaceuticals Secures $69.3 Million Government Contract to Manufacture Critical Medicines in the U.S.